Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458453 | 1.00 | HTT (0.47) | HTTPOLBNPSR1MEN1KMT2A | |
| Acetic Acid SCHEMBL21519581 | 0.92 | CYP1A2 (0.49) | HTTPOLBNPSR1MEN1KMT2A | |
| SCHEMBL5462172 | 0.89 | POLB (0.39) | HTTPOLBNPSR1KMT2AMAPT | |
| SCHEMBL5462169 | 0.89 | POLB (0.39) | HTTPOLBNPSR1KMT2AMAPT | |
| Guanabenz SCHEMBL6302549 | 0.89 | POLB (0.57) | HTTPOLBNPSR1MEN1KMT2A | |
| Guanabenz SCHEMBL4103258 | 0.89 | POLB (0.57) | HTTPOLBNPSR1MEN1KMT2A | |
| Guanabenz SCHEMBL15389 | 0.89 | POLB (0.57) | HTTPOLBNPSR1MEN1KMT2A | |
| Guanabenz SCHEMBL22616213 | 0.87 | POLB (0.55) | HTTPOLBNPSR1MEN1KMT2A | |
| Guanabenz SCHEMBL11685908 | 0.87 | POLB (0.55) | HTTPOLBNPSR1MEN1KMT2A | |
| Guanabenz SCHEMBL22616212 | 0.87 | POLB (0.55) | HTTPOLBNPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | NAFTCHI N E | 2007-04-12 | — | — | US | disclosed |
| US-7109329-B2 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC | 2006-09-19 | — | — | US | disclosed |
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC (US) | 2004-05-13 | — | — | US | disclosed |
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | disclosed |
| US-5958933-A | HAVING A GUANIDINO GROUP ALIPHATICALLY LINKED TO A XANTHINE GROUP, ADRENERGIC STIMULANTS | NAFTCHI N ERIC (US) | 1999-09-28 | — | — | US | disclosed |
| US-4060640-A | O-HALOBENZYLIDENEAMINO GUANIDINES, CNS DEPRESSANT | SHELL OIL COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
| US-3975533-A | O-HALOBENZYLIDENEAMINOGUANIDINES, ANTIDEPRESSANT | SHELL OIL COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | HTT 766/4885POLB 4376/4885NPSR1 82/4885 |
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | ACHE, GRIN2A, GRIK2 | HTT 62/4885POLB 2977/4885NPSR1 2024/4885 |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | ADRB2, ADRB1, CHRNA7 | HTT 1343/4885POLB 2849/4885NPSR1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.